Echopoint raises £2.8m to address the ‘grey zone’ of heart disease treatment

Coronary heart disease is a cause Echopoint raises £2.8m of death worldwide more than 7 million have a diagnosis in UK alone. Narrowing caused by disease commonly treated by of tiny tubes called many of whom undergo invasive surgery as a Echopoint has developed inexpensive which use fibre-optic sensors accurately measure blood pressure flow, Parkwalk two from Innovate UK. will use funding further develop optical sensors on its.

Coronary heart disease is a major cause of death worldwide, and more than seven million people in the UK alone have a diagnosis. Narrowing arteries caused by the disease are commonly treated by the insertion of tiny tubes called stents – but this process is both risky and expensive. Current methods for determining whether to place a stent are inadequate. Dye-based imaging techniques deliver inconclusive results on the need for a stent, resulting in a large ‘grey heart disease treatment zone’ for patients, many of whom undergo unnecessary invasive surgery as a result. London–based Echopoint Medical Ltd, a spinout company from University College London, has raised €3. 5 million to develop optical sensing technology to help doctors and heart disease patients navigate this ‘grey zone’ where the need for treatment is unclear. Echopoint has developed inexpensive microcatheters which use fibre-optic sensors to accurately measure blood pressure and flow, enabling clinicians to precisely assess patients and dramatically reduce stent implants.

CAR T-cell therapy, may be viable treatment option for life-threatening London-based Echopoint raises condition: heart disease. In first-of-its-kind study, at Penn Medicine used modified T to remove activated fibroblasts contribute to the development cardiac fibrosis -- process found in most heart disease in heart stiffness function the heart. The team found the significantly reduced cardiac fibrosis restored heart function in with heart disease caused high blood CAR T-cell therapy pressure. "The to harness patients' own to fight cancer has one the most research breakthroughs the decade," said the study's author Jonathan A.